Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer

Sridhar Mani, U. Swami

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Eisai is developing eribulin mesilate (E-7389), a synthetic macrocyclic ketone analogue of the tubulin inhibitor halichondrin B, for the treatment of a variety of solid tumors that include but are not limited to breast and lung cancer. In this context, eribulin is in phase III clinical trials in breast cancer; however, it has also progressed to phase II for non-small cell lung cancer, soft tissue sarcomas, pancreatic, prostate, head and neck cancer, bladder and ovarian and related gynecological tumors. Eribulin has shown synergistic in vitro antiproliferative activity in combination with the breast cancer drugs gemcitabine, epirubicin, trastuzumab, docetaxel and vinorelbine. Clinical trials have established efficacy, safety and a distinct survival advantage of 2.5 months with eribulin as compared to other treatments of physician's choice in metastatic breast cancer patients with heavy pretreatment and taxane resistance. It has a manageable side effect profile, consisting mostly of neutropenia and fatigue, with distinct tolerance at full doses in renal dysfunction, a lower incidence of peripheral neuropathy, minimal chances of drug-drug interactions and hypersensitivity. It appears to be a suitable candidate for third-line monotherapy and beyond for locally advanced and metastatic breast cancer. This review will focus on published and peer-reviewed data on breast cancer.

Original languageEnglish (US)
Pages (from-to)641-653
Number of pages13
JournalDrugs of Today
Volume46
Issue number9
DOIs
StatePublished - Sep 2010

Fingerprint

eribulin
Mesylates
Breast Neoplasms
docetaxel
gemcitabine
Therapeutics
Tubulin Modulators
Drug Hypersensitivity
Epirubicin
Phase III Clinical Trials
Peripheral Nervous System Diseases
Head and Neck Neoplasms
Neutropenia
Ketones
Pancreatic Neoplasms
Drug Interactions
Urinary Bladder Neoplasms
Non-Small Cell Lung Carcinoma
Sarcoma
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer. / Mani, Sridhar; Swami, U.

In: Drugs of Today, Vol. 46, No. 9, 09.2010, p. 641-653.

Research output: Contribution to journalArticle

@article{da64318c4c5744a4b9ac4c2819adc658,
title = "Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer",
abstract = "Eisai is developing eribulin mesilate (E-7389), a synthetic macrocyclic ketone analogue of the tubulin inhibitor halichondrin B, for the treatment of a variety of solid tumors that include but are not limited to breast and lung cancer. In this context, eribulin is in phase III clinical trials in breast cancer; however, it has also progressed to phase II for non-small cell lung cancer, soft tissue sarcomas, pancreatic, prostate, head and neck cancer, bladder and ovarian and related gynecological tumors. Eribulin has shown synergistic in vitro antiproliferative activity in combination with the breast cancer drugs gemcitabine, epirubicin, trastuzumab, docetaxel and vinorelbine. Clinical trials have established efficacy, safety and a distinct survival advantage of 2.5 months with eribulin as compared to other treatments of physician's choice in metastatic breast cancer patients with heavy pretreatment and taxane resistance. It has a manageable side effect profile, consisting mostly of neutropenia and fatigue, with distinct tolerance at full doses in renal dysfunction, a lower incidence of peripheral neuropathy, minimal chances of drug-drug interactions and hypersensitivity. It appears to be a suitable candidate for third-line monotherapy and beyond for locally advanced and metastatic breast cancer. This review will focus on published and peer-reviewed data on breast cancer.",
author = "Sridhar Mani and U. Swami",
year = "2010",
month = "9",
doi = "10.1358/dot.2010.46.9.1519020",
language = "English (US)",
volume = "46",
pages = "641--653",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "9",

}

TY - JOUR

T1 - Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer

AU - Mani, Sridhar

AU - Swami, U.

PY - 2010/9

Y1 - 2010/9

N2 - Eisai is developing eribulin mesilate (E-7389), a synthetic macrocyclic ketone analogue of the tubulin inhibitor halichondrin B, for the treatment of a variety of solid tumors that include but are not limited to breast and lung cancer. In this context, eribulin is in phase III clinical trials in breast cancer; however, it has also progressed to phase II for non-small cell lung cancer, soft tissue sarcomas, pancreatic, prostate, head and neck cancer, bladder and ovarian and related gynecological tumors. Eribulin has shown synergistic in vitro antiproliferative activity in combination with the breast cancer drugs gemcitabine, epirubicin, trastuzumab, docetaxel and vinorelbine. Clinical trials have established efficacy, safety and a distinct survival advantage of 2.5 months with eribulin as compared to other treatments of physician's choice in metastatic breast cancer patients with heavy pretreatment and taxane resistance. It has a manageable side effect profile, consisting mostly of neutropenia and fatigue, with distinct tolerance at full doses in renal dysfunction, a lower incidence of peripheral neuropathy, minimal chances of drug-drug interactions and hypersensitivity. It appears to be a suitable candidate for third-line monotherapy and beyond for locally advanced and metastatic breast cancer. This review will focus on published and peer-reviewed data on breast cancer.

AB - Eisai is developing eribulin mesilate (E-7389), a synthetic macrocyclic ketone analogue of the tubulin inhibitor halichondrin B, for the treatment of a variety of solid tumors that include but are not limited to breast and lung cancer. In this context, eribulin is in phase III clinical trials in breast cancer; however, it has also progressed to phase II for non-small cell lung cancer, soft tissue sarcomas, pancreatic, prostate, head and neck cancer, bladder and ovarian and related gynecological tumors. Eribulin has shown synergistic in vitro antiproliferative activity in combination with the breast cancer drugs gemcitabine, epirubicin, trastuzumab, docetaxel and vinorelbine. Clinical trials have established efficacy, safety and a distinct survival advantage of 2.5 months with eribulin as compared to other treatments of physician's choice in metastatic breast cancer patients with heavy pretreatment and taxane resistance. It has a manageable side effect profile, consisting mostly of neutropenia and fatigue, with distinct tolerance at full doses in renal dysfunction, a lower incidence of peripheral neuropathy, minimal chances of drug-drug interactions and hypersensitivity. It appears to be a suitable candidate for third-line monotherapy and beyond for locally advanced and metastatic breast cancer. This review will focus on published and peer-reviewed data on breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=79955887466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955887466&partnerID=8YFLogxK

U2 - 10.1358/dot.2010.46.9.1519020

DO - 10.1358/dot.2010.46.9.1519020

M3 - Article

C2 - 20967296

AN - SCOPUS:79955887466

VL - 46

SP - 641

EP - 653

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 9

ER -